Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to 18.64%.

  • Sanara MedTech's EBITDA Margin rose 68100.0% to 18.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.72%, marking a year-over-year increase of 7000.0%. This contributed to the annual value of 3.11% for FY2024, which is 29100.0% up from last year.
  • According to the latest figures from Q3 2025, Sanara MedTech's EBITDA Margin is 18.64%, which was up 68100.0% from 10.32% recorded in Q2 2025.
  • Over the past 5 years, Sanara MedTech's EBITDA Margin peaked at 18.64% during Q3 2025, and registered a low of 47.19% during Q4 2021.
  • In the last 5 years, Sanara MedTech's EBITDA Margin had a median value of 7.14% in 2023 and averaged 10.13%.
  • Per our database at Business Quant, Sanara MedTech's EBITDA Margin crashed by -297600bps in 2021 and then surged by 320800bps in 2023.
  • Sanara MedTech's EBITDA Margin (Quarter) stood at 47.19% in 2021, then skyrocketed by 58bps to 19.69% in 2022, then skyrocketed by 113bps to 2.54% in 2023, then plummeted by -460bps to 9.14% in 2024, then soared by 304bps to 18.64% in 2025.
  • Its last three reported values are 18.64% in Q3 2025, 10.32% for Q2 2025, and 2.81% during Q1 2025.